On its way out the door, the Biden Administration just released new guidelines for those seeking to license inventions made at the National Institutes of Health (NIH) that could lead to new “drugs, biologics (including vaccines) or devices for the prevention, diagnosis or treatment of human disease.” The administration has claimed this is being done “to expand patient access to products that emerge from NIH-owned inventions.” The guidelines apply to all licenses, exclusive and non-exclusive.
Recent Posts
- Other Barks & Bites for Friday, April 11: CAFC Denies Transfer of EDTX Patent Case; Texas Leads Entire U.S. in IP Exports; and Google Declines to Respond to Cellspin Soft Cert Petition
- Federal Circuit Issues Precedential Order Denying Mandamus Relief for SAP, Despite District Court Errors
- CAFC Affirms Dismissal of Opposition to iVoters Marks But Hints USPTO Should Reconsider Registration
- Why Creativity and Ownership Are Crucial to Innovation | IPWatchdog Unleashed
- Can Judge Hughes Course Correct the CAFC on Prosecution Laches?